CONNECT WITH US
HealthTech

HealthTech

Key immune driver of pancreatic cancer points to combination treatment for slowing progression

Medical Xpress logo

Published on

Add as a preferred source on Google
Key immune driver of pancreatic cancer points to combination treatment for slowing progression

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Researchers from The University of Texas MD Anderson Cancer Center have discovered that the IL-18 inflammatory protein helps pancreatic tumors grow and evade the immune system, highlighting its potential as a therapeutic target for pancreatic cancer.

Reducing levels of IL-18 in preclinical models reshaped the tumor microenvironment, slowed tumor growth, improved survival and enhanced the effects of KRAS-targeted therapies.

The study, published in Gastroenterology, was co-led by Yang Chen, Ph.D., assistant professor of Translational Molecular Pathology, and Xinlei Sun, Ph.D., postdoctoral fellow in Translational Molecular Pathology.

"Our results show that IL-18 helps pancreatic tumors stay hidden from the immune system and significantly contributes to disease progression and reduced survival," Chen said. "Finding a way to safely target IL-18 in humans could have tremendous potential for enhancing the benefits of KRAS-targeted therapies and improving patient outcomes."

IL-18 is a pro-inflammatory protein that helps regulate the immune response. It is known to be elevated in pancreatic cancer and is typically associated with poor patient outcomes. To understand its role, the researchers created genetically engineered models of pancreatic cancer with reduced IL-18 protein levels and examined the resulting tumor microenvironment. Reducing IL-18 delayed disease progression and extended survival in these models.

Further single-cell analyses revealed that IL-18 increases levels of CD47, a protein that is known as the "don't eat me" signal because it helps cancer cells avoid being cleared by macrophage immune cells.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.